Natera

The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.

Of the 29 companies in the index, 18 companies' share prices declined while the share values of 11 increased month over month.

If the underwriters exercise their option to purchase the over-allotment in full, total gross proceeds from the offering would be $230 million.

The company said it processed around 200,000 tests in the third quarter, representing approximately 20 percent growth over the year-ago quarter.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.